Needham Maintains Buy on Viridian Therapeutics, Raises Price Target to $38
Benzinga Newsdesk 20 hours ago
Analyst RatingsNewsPrice Target
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $34 to $38.
Needham analyst Serge Belanger maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and raises the price target from $34 to $38.